DK0942729T3 - Anvendelse af NK-1-receptorantagonister til behandling af stresslidelser - Google Patents

Anvendelse af NK-1-receptorantagonister til behandling af stresslidelser

Info

Publication number
DK0942729T3
DK0942729T3 DK97952020T DK97952020T DK0942729T3 DK 0942729 T3 DK0942729 T3 DK 0942729T3 DK 97952020 T DK97952020 T DK 97952020T DK 97952020 T DK97952020 T DK 97952020T DK 0942729 T3 DK0942729 T3 DK 0942729T3
Authority
DK
Denmark
Prior art keywords
treatment
stress disorders
receptor antagonists
receptor antagonist
stress
Prior art date
Application number
DK97952020T
Other languages
English (en)
Inventor
Raymond Baker
Neil Roy Curtis
Jason Matthew Elliott
Timothy Harrison
Gregory John Hollingworth
Philip Stephen Jackson
Janusz Jozef Kulagowski
Nadia Melanie Rupniak
Eileen Mary Seward
Christopher John Swain
Brian John Williams
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27517387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0942729(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB9625051A external-priority patent/GB9625051D0/en
Priority claimed from GB9701459A external-priority patent/GB9701459D0/en
Priority claimed from GB9713715A external-priority patent/GB9713715D0/en
Priority claimed from GB9716482A external-priority patent/GB9716482D0/en
Priority claimed from GB9721171A external-priority patent/GB9721171D0/en
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of DK0942729T3 publication Critical patent/DK0942729T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK97952020T 1996-12-02 1997-11-25 Anvendelse af NK-1-receptorantagonister til behandling af stresslidelser DK0942729T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9625051A GB9625051D0 (en) 1996-12-02 1996-12-02 Therapeutic agents
GB9701459A GB9701459D0 (en) 1997-01-24 1997-01-24 Therapeutic agents
GB9713715A GB9713715D0 (en) 1997-06-27 1997-06-27 Therapeutic agents
GB9716482A GB9716482D0 (en) 1997-08-04 1997-08-04 Therapeutic agents
GB9721171A GB9721171D0 (en) 1997-10-07 1997-10-07 Therapeutic use
EP97952020A EP0942729B1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating stress disorders

Publications (1)

Publication Number Publication Date
DK0942729T3 true DK0942729T3 (da) 2005-01-10

Family

ID=27517387

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97952020T DK0942729T3 (da) 1996-12-02 1997-11-25 Anvendelse af NK-1-receptorantagonister til behandling af stresslidelser

Country Status (11)

Country Link
EP (1) EP0942729B1 (da)
JP (1) JP2001504849A (da)
AT (1) ATE274908T1 (da)
AU (1) AU731676B2 (da)
CA (1) CA2273786A1 (da)
CY (1) CY2499B1 (da)
DE (1) DE69730515T2 (da)
DK (1) DK0942729T3 (da)
ES (1) ES2227728T3 (da)
PT (1) PT942729E (da)
WO (1) WO1998024440A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2334611A1 (en) * 1998-06-11 1999-12-16 Merck Sharp & Dohme Limited Use of a nk-1 receptor antagonist for treating psychiatric disorders
EP1085875A1 (en) * 1998-06-11 2001-03-28 MERCK SHARP & DOHME LTD. Use of a nk-1 receptor antagonist for treating psychiatric disorders
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4002840A1 (de) * 1990-01-29 1991-08-01 Gerhard Dr Stechmesser Verfahren zur bekaempfung stressinduzierter dysregulationen
EP0528495A1 (en) * 1991-08-20 1993-02-24 Merck Sharp & Dohme Ltd. Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them
IL106142A (en) * 1992-06-29 1997-03-18 Merck & Co Inc Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them
US5496833A (en) * 1993-04-13 1996-03-05 Merck Sharp & Dohme Limited Piperidine tachykinin receptor antagonists
IS4208A (is) * 1993-09-22 1995-03-23 Glaxo Group Limited 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður
EP1462450B1 (en) * 1993-12-29 2007-06-13 MERCK SHARP & DOHME LTD. Substituted morpholine derivatives and their use as therapeutic agents
AU691327B2 (en) * 1994-08-15 1998-05-14 Merck Sharp & Dohme Limited Morpholine derivatives and their use as therapeutic agents

Also Published As

Publication number Publication date
AU731676B2 (en) 2001-04-05
EP0942729B1 (en) 2004-09-01
EP0942729A1 (en) 1999-09-22
CA2273786A1 (en) 1998-06-11
WO1998024440A1 (en) 1998-06-11
DE69730515D1 (de) 2004-10-07
CY2499B1 (en) 2005-09-02
AU5559098A (en) 1998-06-29
JP2001504849A (ja) 2001-04-10
ES2227728T3 (es) 2005-04-01
DE69730515T2 (de) 2005-09-01
PT942729E (pt) 2004-12-31
ATE274908T1 (de) 2004-09-15

Similar Documents

Publication Publication Date Title
DK1685839T3 (da) Farmaceutisk oral doseringsform omfattende en kombination af en opioidagonist og opioidantagonist
DE69831869D1 (de) Verbesserte verabreichungstechnik für multiple medikamentengaben
HUP0302131A2 (hu) Gyógyászati tramadolsók, ezeket tartalmazó gyógyszerkészítmények
PT893992E (pt) Formas de dosagem oral de desintegracao rapida
DK0954314T3 (da) Doseringsformer til bedring af mandlig erektionsdefekt
HUP0203590A2 (hu) Gyógyszerkészítmény a csonttömeg csökkenésével járó betegségek kezelésére
HUP0202862A2 (hu) A loteprednol és antihisztaminok új kombinációját tartalmazó gyógyszerkészítmény
SE9704644D0 (sv) New use
ATE287264T1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
MXPA06002722A (es) Composicion farmaceutica que comprende un antagonista del receptor p2x7 y un farmaco anti-inflamatorio no esteroidal.
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
MXPA02003484A (es) Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural de gaba.
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
SE9903995D0 (sv) New combination
BG105962A (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
NO20014855D0 (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
CY2499B1 (en) Use of nk-1 receptor antagonists for treating stress disorders.
HUP0202931A2 (hu) Egy gyógyszerészetileg hatásos összetétel és a beadására szolgáló készülék
ATE282417T1 (de) Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen
MY128529A (en) Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
ATE282416T1 (de) Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungen
DE69732492D1 (de) Verwendung von nk-1 rezeptorantagonisten zur behandlung von schweren depressionen, die von angstzuständen begleitet werden
DK1420789T3 (da) Anvendelse af aktivstoffer med my-opioid-receptoragonistisk virkning og opioid-receptorantagonistisk virkning som kombinationslægemidler til cancerbehandling
ATE293975T1 (de) Die verwendung von nk-1 rezeptor antagonisten für die behandlung von kognitiven störungen
AU5981200A (en) Transdermal therapeutic system for administering a calcium antagonist